Y. Cheng

发表

Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patients

S. Zhou, Yan Li, N. Chen, 2022, EJHaem.

Model‐based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myeloma

P. Maciag, S. Zhou, Yan Li, 2022, British journal of clinical pharmacology.

A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects

Atalanta Ghosh, S. Zhou, Yan Li, 2023, Clinical pharmacology : advances and applications.

Exposure‐Response Analysis to Assess the Concentration‐QTc Relationship of Iberdomide

S. Zhou, Liangang Liu, Yan Li, 2023, Clinical pharmacology in drug development.

Assessment of Transporter‐Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

S. Zhou, Leon Carayannopoulos, Yan Li, 2021, Journal of clinical pharmacology.

Population Pharmacokinetics of CC-122

S. Zhou, M. Pourdehnad, Jian Chen, 2021, Clinical pharmacology : advances and applications.

An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase

S. Zhou, Liangang Liu, Yan Li, 2022, Journal of clinical pharmacy and therapeutics.

CPAA_A_310604 61..71

S. Zhou, M. Pourdehnad, Jian Chen, 2021 .

Effects of Antitumor Drug Sorafenib on Chick Embryo Development

Guang Wang, M. Chuai, Kenneth K H Lee, 2015, Anatomical record.

Iberdomide (CC-220) Monotherapy or in Combination with an Anti-CD20 Monoclonal Antibody As Effective Therapy in Patients with Relapsed/Refractory Lymphoma: Early Results from a Phase 1/2 Study

I. Flinn, L. Arcaini, C. Visco, 2022, Blood.

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial.

S. Jagannath, S. Lonial, P. Richardson, 2022, The Lancet. Haematology.

An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton’s Tyrosine Kinase Inhibitor

S. Zhou, Liangang Liu, Yan Li, 2022, European Journal of Drug Metabolism and Pharmacokinetics.